Molecular cloning of hMena (ENAH) and its splice variant hMena +11a: Epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines

Francesca Di Modugno, Lucia DeMonte, Michele Balsamo, Giovanna Bronzi, Maria Rita Nicotra, Massimo Alessio, Elke Jager, John S. Condeelis, Angela Santoni, Pier Giorgio Natali, Paola Nisticò

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

hMena (ENAH), an actin regulatory protein involved in the control of cell motility and adhesion, is modulated during human breast carcinogenesis. In fact, whereas undetectable in normal mammary epithelium, hMena becomes overexpressed in high-risk benign lesions and primary and metastatic tumors. In vivo, hMena overexpression correlates with the HER-2+/ER-/ Ki67 + unfavorable prognostic phenotype. In vitro, neuregulin-1 up-regulates whereas Herceptin treatment down-modulates hMena expression, suggesting that it may couple tyrosine kinase receptor signaling to the actin cytoskeleton. Herein, we report the cloning of hMena and of a splice variant, hMena+11a, which contains an additional exon corresponding to 21 amino acids located in the EVH2 domain, from a breast carcinoma cell line of epithelial phenotype. Whereas hMena overexpression consistently characterizes the transformed phenotype of tumor cells of different lineages, hMena +11a isoform is concomitantly present only in epithelial tumor cell lines. In breast cancer cell lines, epidermal growth factor (EGF) treatment promotes concomitant up-regulation of hMena and hMena+11a, resulting in an increase of the fraction of phosphorylated hMena+11a isoform only. hMena+11a overexpression and phosphorylation leads to increased p42/44 mitogen-activated protein kinase (MAPK) activation and cell proliferation as evidenced in hMena+11a-transfected breast cancer cell lines. On the contrary, hMena knockdown induces reduction of p42/44 MAPK phosphorylation and of the proliferative response to EGF. The present data provide new insight into the relevance of actin cytoskeleton regulatory proteins and, in particular, of hMena isoforms in coupling multiple signaling pathways involved in breast cancer.

Original languageEnglish (US)
Pages (from-to)2657-2665
Number of pages9
JournalCancer Research
Volume67
Issue number6
DOIs
StatePublished - Mar 15 2007

Fingerprint

Molecular Cloning
Epidermal Growth Factor
Phosphorylation
Breast Neoplasms
Cell Line
Protein Isoforms
Mitogen-Activated Protein Kinase 1
Actin Cytoskeleton
Phenotype
Breast
Up-Regulation
Neuregulin-1
Receptor Protein-Tyrosine Kinases
Cell Lineage
Tumor Cell Line
Cell Adhesion
Cell Movement
Actins
Organism Cloning
Exons

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular cloning of hMena (ENAH) and its splice variant hMena +11a : Epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. / Di Modugno, Francesca; DeMonte, Lucia; Balsamo, Michele; Bronzi, Giovanna; Nicotra, Maria Rita; Alessio, Massimo; Jager, Elke; Condeelis, John S.; Santoni, Angela; Natali, Pier Giorgio; Nisticò, Paola.

In: Cancer Research, Vol. 67, No. 6, 15.03.2007, p. 2657-2665.

Research output: Contribution to journalArticle

Di Modugno, Francesca ; DeMonte, Lucia ; Balsamo, Michele ; Bronzi, Giovanna ; Nicotra, Maria Rita ; Alessio, Massimo ; Jager, Elke ; Condeelis, John S. ; Santoni, Angela ; Natali, Pier Giorgio ; Nisticò, Paola. / Molecular cloning of hMena (ENAH) and its splice variant hMena +11a : Epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. In: Cancer Research. 2007 ; Vol. 67, No. 6. pp. 2657-2665.
@article{9d9b0773393c4fbb908a717b01995bac,
title = "Molecular cloning of hMena (ENAH) and its splice variant hMena +11a: Epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines",
abstract = "hMena (ENAH), an actin regulatory protein involved in the control of cell motility and adhesion, is modulated during human breast carcinogenesis. In fact, whereas undetectable in normal mammary epithelium, hMena becomes overexpressed in high-risk benign lesions and primary and metastatic tumors. In vivo, hMena overexpression correlates with the HER-2+/ER-/ Ki67 + unfavorable prognostic phenotype. In vitro, neuregulin-1 up-regulates whereas Herceptin treatment down-modulates hMena expression, suggesting that it may couple tyrosine kinase receptor signaling to the actin cytoskeleton. Herein, we report the cloning of hMena and of a splice variant, hMena+11a, which contains an additional exon corresponding to 21 amino acids located in the EVH2 domain, from a breast carcinoma cell line of epithelial phenotype. Whereas hMena overexpression consistently characterizes the transformed phenotype of tumor cells of different lineages, hMena +11a isoform is concomitantly present only in epithelial tumor cell lines. In breast cancer cell lines, epidermal growth factor (EGF) treatment promotes concomitant up-regulation of hMena and hMena+11a, resulting in an increase of the fraction of phosphorylated hMena+11a isoform only. hMena+11a overexpression and phosphorylation leads to increased p42/44 mitogen-activated protein kinase (MAPK) activation and cell proliferation as evidenced in hMena+11a-transfected breast cancer cell lines. On the contrary, hMena knockdown induces reduction of p42/44 MAPK phosphorylation and of the proliferative response to EGF. The present data provide new insight into the relevance of actin cytoskeleton regulatory proteins and, in particular, of hMena isoforms in coupling multiple signaling pathways involved in breast cancer.",
author = "{Di Modugno}, Francesca and Lucia DeMonte and Michele Balsamo and Giovanna Bronzi and Nicotra, {Maria Rita} and Massimo Alessio and Elke Jager and Condeelis, {John S.} and Angela Santoni and Natali, {Pier Giorgio} and Paola Nistic{\`o}",
year = "2007",
month = "3",
day = "15",
doi = "10.1158/0008-5472.CAN-06-1997",
language = "English (US)",
volume = "67",
pages = "2657--2665",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Molecular cloning of hMena (ENAH) and its splice variant hMena +11a

T2 - Epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines

AU - Di Modugno, Francesca

AU - DeMonte, Lucia

AU - Balsamo, Michele

AU - Bronzi, Giovanna

AU - Nicotra, Maria Rita

AU - Alessio, Massimo

AU - Jager, Elke

AU - Condeelis, John S.

AU - Santoni, Angela

AU - Natali, Pier Giorgio

AU - Nisticò, Paola

PY - 2007/3/15

Y1 - 2007/3/15

N2 - hMena (ENAH), an actin regulatory protein involved in the control of cell motility and adhesion, is modulated during human breast carcinogenesis. In fact, whereas undetectable in normal mammary epithelium, hMena becomes overexpressed in high-risk benign lesions and primary and metastatic tumors. In vivo, hMena overexpression correlates with the HER-2+/ER-/ Ki67 + unfavorable prognostic phenotype. In vitro, neuregulin-1 up-regulates whereas Herceptin treatment down-modulates hMena expression, suggesting that it may couple tyrosine kinase receptor signaling to the actin cytoskeleton. Herein, we report the cloning of hMena and of a splice variant, hMena+11a, which contains an additional exon corresponding to 21 amino acids located in the EVH2 domain, from a breast carcinoma cell line of epithelial phenotype. Whereas hMena overexpression consistently characterizes the transformed phenotype of tumor cells of different lineages, hMena +11a isoform is concomitantly present only in epithelial tumor cell lines. In breast cancer cell lines, epidermal growth factor (EGF) treatment promotes concomitant up-regulation of hMena and hMena+11a, resulting in an increase of the fraction of phosphorylated hMena+11a isoform only. hMena+11a overexpression and phosphorylation leads to increased p42/44 mitogen-activated protein kinase (MAPK) activation and cell proliferation as evidenced in hMena+11a-transfected breast cancer cell lines. On the contrary, hMena knockdown induces reduction of p42/44 MAPK phosphorylation and of the proliferative response to EGF. The present data provide new insight into the relevance of actin cytoskeleton regulatory proteins and, in particular, of hMena isoforms in coupling multiple signaling pathways involved in breast cancer.

AB - hMena (ENAH), an actin regulatory protein involved in the control of cell motility and adhesion, is modulated during human breast carcinogenesis. In fact, whereas undetectable in normal mammary epithelium, hMena becomes overexpressed in high-risk benign lesions and primary and metastatic tumors. In vivo, hMena overexpression correlates with the HER-2+/ER-/ Ki67 + unfavorable prognostic phenotype. In vitro, neuregulin-1 up-regulates whereas Herceptin treatment down-modulates hMena expression, suggesting that it may couple tyrosine kinase receptor signaling to the actin cytoskeleton. Herein, we report the cloning of hMena and of a splice variant, hMena+11a, which contains an additional exon corresponding to 21 amino acids located in the EVH2 domain, from a breast carcinoma cell line of epithelial phenotype. Whereas hMena overexpression consistently characterizes the transformed phenotype of tumor cells of different lineages, hMena +11a isoform is concomitantly present only in epithelial tumor cell lines. In breast cancer cell lines, epidermal growth factor (EGF) treatment promotes concomitant up-regulation of hMena and hMena+11a, resulting in an increase of the fraction of phosphorylated hMena+11a isoform only. hMena+11a overexpression and phosphorylation leads to increased p42/44 mitogen-activated protein kinase (MAPK) activation and cell proliferation as evidenced in hMena+11a-transfected breast cancer cell lines. On the contrary, hMena knockdown induces reduction of p42/44 MAPK phosphorylation and of the proliferative response to EGF. The present data provide new insight into the relevance of actin cytoskeleton regulatory proteins and, in particular, of hMena isoforms in coupling multiple signaling pathways involved in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=34047257715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047257715&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-1997

DO - 10.1158/0008-5472.CAN-06-1997

M3 - Article

C2 - 17363586

AN - SCOPUS:34047257715

VL - 67

SP - 2657

EP - 2665

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 6

ER -